Sugi Predict

Sugi Predict / Compounds / SCHEMBL23623240

SCHEMBL23623240

SCHEMBL23623240

O=C(NCc1cc(-c2cccs2)[nH]n1)c1ccccc1N1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ MAPT P10636 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ KDM5B Q9UGL1 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ AURKA O14965 1/20 0.41
▸ AURKB Q96GD4 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ HPGD P15428 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ LIPG Q9Y5X9 2/20 0.40
▸ CHEK1 O14757 1/20 0.39
▸ HTT P42858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23623631 1.00 KMT2A (0.45) KMT2AMEN1L3MBTL1MAPTLMNA
SCHEMBL23623306 0.99 KMT2A (0.46) KMT2AMEN1L3MBTL1MAPTLMNA
SCHEMBL23623302 0.91 FLT3 (0.48) KMT2AMEN1L3MBTL1MAPTLMNA
SCHEMBL23623241 0.90 GAA (0.45) KMT2AMEN1L3MBTL1MAPTLMNA
SCHEMBL23623300 0.89 KMT2A (0.42) KMT2AMEN1L3MBTL1MAPTLMNA
SCHEMBL23644226 0.89 KMT2A (0.44) KMT2AMEN1L3MBTL1MAPTLMNA
SCHEMBL23623243 0.89 KMT2A (0.42) KMT2AMEN1L3MBTL1MAPTLMNA
SCHEMBL23611734 0.89 ALDH1A1 (0.42) KMT2AMEN1L3MBTL1MAPTLMNA
SCHEMBL29930673 0.89 ALDH1A1 (0.42) KMT2AMEN1L3MBTL1MAPTLMNA
SCHEMBL23623305 0.88 HDAC3 (0.41) KMT2AMEN1L3MBTL1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091590-A1 COMPOUNDS FOR USE IN TREATING GASTRIC CANCER BERG LLC (US) 2023-05-25 — — WO disclosed
US-20220002255-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE THLIVERIS, ANDREW T. 2022-01-06 — — US disclosed
US-11091447-B2 UBE2K modulators and methods for their use BERG LLC (US) 2021-08-17 — — US disclosed
US-20210214320-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE THLIVERIS, ANDREW T. 2021-07-15 — — US disclosed
WO-2021138540-A1 POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER BERG LLC (US) 2021-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091447-B2 UBE2K modulators and methods for their use UBE2N, UBE2B, UBE2E1 KMT2A 1523/4885MEN1 4260/4885L3MBTL1 4151/4885
US-20220002255-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE UBE2N, UBE2B, UBE2E1 KMT2A 1523/4885MEN1 4260/4885L3MBTL1 4151/4885
US-20210214320-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE UBE2N, UBE2B, UBE2E1 KMT2A 1523/4885MEN1 4260/4885L3MBTL1 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.